Skip to main content
. 2022 Aug 3;7(5):734–743. doi: 10.1182/bloodadvances.2022008259

Table 1.

Characteristics of 4023 patients with MPN, 2010-2017

Overall, n (%) Hydroxyurea, n (%)
Yes No P
Total 4023 2683 1340
Type of MPN
 PV 1688 (42.0) 1017 (37.9) 671 (50.1) <.01
 ET 1976 (49.1) 1548 (57.7) 428 (31.9)
 MF 359 (8.9) 118 (4.4) 241 (18.0)
Age, y
 Median (IQR) 77 (71-83) 76 (71-83) 77 (72-83)
 66-69 683 (17.0) 412 (15.4) 271 (20.2) <.01
 70-74 927 (23.0) 601 (22.4) 326 (24.3)
 75-79 845 (21.0) 594 (22.1) 251 (18.7)
 80-84 769 (19.1) 536 (20.0) 233 (17.4)
 ≥85 799 (19.9) 540 (20.1) 259 (19.3)
Sex
 Female 2468 (61.3) 1771 (66.0) 697 (52.0) <.01
 Male 1555 (38.7) 912 (34.0) 643 (48.0)
Race
 White 3469 (86.2) 2323 (86.6) 1146 (85.5) .36
 Other 554 (13.8) 360 (13.4) 194 (14.5)
Marital status
 Single 1341 (33.3) 897 (33.4) 444 (33.1) .26
 Married 2362 (58.7) 1560 (58.1) 802 (59.9)
 Unknown 320 (8.0) 226 (8.4) 94 (7.0)
Region
 Northeast 1794 (44.6) 1168 (43.5) 626 (46.7) <.01
 Midwest 370 (9.2) 275 (10.2) 95 (7.1)
 South 753 (18.7) 468 (17.4) 285 (21.3)
 West 1106 (27.5) 772 (28.8) 334 (24.9)
Elixhauser Comorbidity Index
 0 506 (12.6) 344 (12.8) 162 (12.1) <.01
 1-2 1609 (40.0) 1141 (42.5) 468 (34.9)
 ≥3 1908 (47.4) 1198 (44.7) 710 (53.0)
Previous cancer
 No 3059 (76.0) 2046 (76.3) 1013 (75.6) .64
 Yes 964 (24.0) 637 (23.7) 327 (24.4)
Disability
 No 3563 (88.6) 2392 (89.2) 1171 (87.4) .10
 Yes 460 (11.4) 291 (10.8) 169 (12.6)
Yost index
 Fifth quintile (highest SES) 899 (33.5) 426 (31.8) .22
 Fourth quintile 1325 (32.9) 551 (20.5) 277 (20.7)
 Third quintile 828 (20.6) 424 (15.8) 223 (16.6)
 Second quintile 647 (16.1) 418 (15.6) 200 (14.9)
 First quintile (lowest SES) 618 (15.4) 267 (10.0) 164 (12.2)
 Unknown 431 (10.7) 124 (4.6) 50 (3.7)
State buy-in
 No 3355 (83.4) 2263 (84.3) 1092 (81.5) .02
 Yes 668 (16.6) 420 (15.7) 248 (18.5)